ClinicalTrials.gg
Active, not recruitingNCT05067790ASCENDUpdated May 22, 2026

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

A Phase 3 interventional study of Nusinersen in Spinal Muscular Atrophy, sponsored by Biogen. Active, not recruiting at 22 sites in 5 countries. Open to participants aged 15 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
15 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing nusinersen in Muscular Atrophy, Spinal — 3 open to participants now, 4 under way, 2 of them phase 3. nusinersen · Muscular Atrophy, Spinal.

Enrollment
9th of 19
45 · median 34
Started
2022
with 1 other
Phase 3
7 of 19
1 open now
Registered
16th of 19
by date
Lead sponsor
15 of 19
Biogen

Among the 19 studies testing nusinersen in Muscular Atrophy, Spinal, this one is the 9th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 3, and was the 16th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

3 of the 19 studies testing nusinersen in Muscular Atrophy, Spinal are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nusinersen

nusinersen: first FDA approval 2016 (SPINRAZA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 15 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nusinersen in Muscular Atrophy, Spinal, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the use of a higher dose of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA). This study will focus on teenagers and adults who are unable to walk on their own and who have previously taken another drug for SMA called risdiplam.

The main goal of this study is to learn about the effect of high dose (HD) nusinersen on muscle and movement ability (motor function) in SMA. The main question that researchers want to answer is:

- How do the scores of a movement test called the Revised Upper Limb Module change from the start of treatment?

The Revised Upper Limb Module is a test used to measure a participant's ability to do specific tasks that involve their shoulders, arms, wrist, elbows, and hands. It measures the changes in their abilities over time.

Researchers will also learn more about the safety of HD nusinersen. They will check participants for adverse events and changes in vital signs, heart tests, and laboratory tests including blood and urine tests.

The study will be done as follows:

  • Participants will be screened to check if they can join the study.
  • After screening, participants will enter the Core Treatment period.
  • At the start of the Core Treatment period, they will receive 2 "loading" doses of nusinersen. These are 50 mg doses of nusinersen given 2 weeks apart.
  • Afterwards, they will continue to receive "maintenance" doses of nusinersen once every 4 months. These doses will be 28 mg.
  • The Core Treatment period will last about 2 years, with a follow-up visit 4 months after the last dose.
  • Participants who complete the Core Treatment period will have the option to continue receiving 28 mg of nusinersen in the Long-Term Extension (LTE) period for about 2 years. There will also be a follow-up visit 4 months after the last dose.
  • Nusinersen will be given through a lumbar puncture, which involves injecting the drug into the fluid around the spinal cord in the lower back.
  • In total, participants will have up to 18 study visits. They will also be called by researchers after each dose of nusinersen.
  • Participants will stay in the study for about 4.5 years if they complete both the Core Treatment and LTE periods.
Read the detailed description

The primary objective of this study is to evaluate motor function following treatment with HD nusinersen in participants with spinal muscular atrophy (SMA) previously treated with risdiplam.

The secondary objective of this study is to evaluate the safety and tolerability of HD nusinersen in participants with SMA previously treated with risdiplam.

03

Conditions studied

  • Spinal Muscular Atrophy
04

Who can participate

Ages eligible
15 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Genetic documentation of 5q SMA homozygous survival motor neuron-1 (SMN1) gene deletion or mutation or compound heterozygous mutation.
  • Diagnosis of later-onset SMA with symptom onset at age >6 months.
  • Aged ≥15 to ≤50 years at the time of
  • Body weight >20 kg.
  • Received oral risdiplam per the approved label or per the managed access program as follows

    1. Nusinersen-naive participants must have had prior treatment with risdiplam for ≥6 months before enrollment.
    2. Nusinersen-experienced participants must have stopped nusinersen for ≥16 months and must have been on risdiplam for ≥12 months before enrollment.
  • Able to perform the age-appropriate functional assessments in the study.
  • RULM entry item A score ≥3.
  • RULM total score ≥5 and ≤30 at Screening.
  • Nonambulatory, defined as not able to walk 15 feet (4.57 meters) independently without support.
  • Willing to stop risdiplam treatment.
  • Willing and able to start treatment with HD nusinersen.

Key Exclusion Criteria:

  • Any major illness within 1 month before the screening examination or within 1 week prior to Screening and up to first dose administration.
  • Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the Screening Period.
  • Presence of an implanted shunt for the drainage of CSF or of an implanted central nervous system catheter.
  • Permanent tracheostomy or permanent ventilation at Screening.
  • The medical necessity, as defined by the Investigator, for noninvasive ventilation such as bilevel positive airway pressure or continuous positive airway pressure outside of regular sleep hours for any reason other than proactive SMA management, at Screening.
  • History of bacterial meningitis, viral encephalitis, or hydrocephalus.
  • Ongoing medical condition that according to the Investigator would interfere with the conduct and assessments of the study. An example is a medical disability (e.g., wasting or cachexia, severe anemia, and respiratory parameters) that would interfere with the assessment of safety or would compromise the ability of the participant to undergo study procedures.
  • Participants who are pregnant or currently breastfeeding and those intending to become pregnant during the study.
  • Treatment with an drug, biological agent, or device within 30 days or 5 half-lives of the agent, whichever is longer, prior to Screening or anytime during the study; any prior or current treatment with gene therapy for the treatment of SMA.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Higher Dose Nusinersen

    All participants in the core study period, previously treated with risdiplam (nusinersen-naive participants and nusinersen-experienced participants), will receive HD nusinersen, administered as 2 loading doses of 50 milligrams (mg) each, approximately 2 weeks apart, followed by maintenance doses of 28 mg approximately every 4 months. Following the core study period, participants may be given the opportunity to receive maintenance doses of 28 mg nusinersen administered approximately every 4 months up to 2 years during the optional long-term extension (LTE) period.

    Drug: Nusinersen

Interventions

  • Administered as specified in the treatment arm

    Also known as: BIIB058, Spinraza

06

What researchers measure

Primary outcomes

  1. Change in Total Revised Upper Limb Module (RULM) Score

    The RULM is being utilized to assess upper limb functional abilities of participants with SMA. This test consists of upper limb performance items that are reflective of activities of daily living. The RULM is scored from 0 to 37 points, with higher scores indicating better function.

    Time frame: Up to Day 855

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death or in the view of the investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a birth defect, or is a medically important event.

    Time frame: Up to Day 1695

  2. Number of Participants With Change in Clinical Laboratory Parameters, Electrocardiogram (ECG), Vital Signs and Pulse Oximetry from Baseline

    Time frame: Up to Day 1695

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Sep 2027, 68 months after the start.

Of 18 phase 3 interventional studies under Muscular Atrophy, Spinal, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2021
First posted
Oct 5, 2021
StartActual
Jan 21, 2022
Primary completionEst.
Sep 24, 2027
CompletionEst.
Sep 24, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05067790
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Jan 21, 2022
Primary completion
Sep 24, 2027 (estimated)
Completion
Sep 24, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nusinersen

Start the discussion